| Assessment Status | NCPE Assessment process complete |
| HTA ID | - |
| Drug | Crizotinib |
| Brand | Xalkori® |
| Indication | Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd–line treatment setting) |
| Assessment Process | |
| Rapid review commissioned | 09/01/2013 |
| Rapid review completed | 31/01/2013 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 24/05/2013 |
| NCPE assessment completed | 27/08/2013 |
| NCPE assessment outcome | Reimbursement not recommended. The NCPE do not consider Crizotinib (Xalkori®) a cost-effective treatment for adult patients with previously treated ALK positive advanced non small cell lung cancer (NSCLC). |
August 2015
The HSE has approved reimbursement following confidential price negotiations.
